MS Clinical Trials


M18-918

A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Efficacy of Elezanumab when Added to Standard of Care in Relapsing Forms of Multiple Sclerosis

Description
The MS Center at EvergreenHealth is conducting a study is to see if a study drug, elezanumab, is safe and works when added to the current treatment in adult subjects with relapsing forms of multiple sclerosis (RMS).

Currently enrolling

Who may be eligible to participate?
Patients 18-55 years of age with a confirmed diagnosis of relapsing remitting multiple sclerosis (RRMS) or secondary-progressive multiple sclerosis (SPMS). Other inclusion/exclusion criteria apply.

What does participation involve?
Participation in this study will last approximately 532 days (around 18-19 months), plus time for screening (up to 4 weeks, if needed). Subjects will be required to participate in 17 in-clinic study visits to receive study drug or placebo, blood draws and/or follow-up assessments/questionnaires.

Investigator: Theodore Brown, MD, MPH

For more information: contact EvergreenHealth Research Services at 425.899.5385 or email EvergreenResearch@evergreenhealth.com


M14-397

A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Efficacy of Elezanumab when Added to Standard of Care in Progressive Forms of Multiple Sclerosis

Description
The MS Center at EvergreenHealth is conducting a study is to see if a study drug, elezanumab, is safe and works when added to the current treatment in adult subjects with progressive forms of multiple sclerosis (PMS).

Currently enrolling

Who may be eligible to participate?
Patients 18-55 years of age with a confirmed diagnosis of primary-progressive multiple sclerosis (PPMS) or secondary-progressive multiple sclerosis (SPMS). Other inclusion/exclusion criteria apply.

What does participation involve?
Participation in this study will last approximately 532 days (around 18-19 months), plus time for screening (up to 4 weeks, if needed). Subjects will be required to participate in 17 in-clinic study visits to receive study drug or placebo, blood draws and/or follow-up assessments/questionnaires.

Investigator: Theodore Brown, MD, MPH

For more information: contact EvergreenHealth Research Services at 425.899.5385 or email EvergreenResearch@evergreenhealth.com


ADS-AMT-MS301

A 16-Week, 3-Arm, Multicenter, Double-Blind, Placebo-Controlled, Randomized Study to Assess the Efficacy and Safety of ADS-5102 Amantadine Extended Release Capsules in Multiple Sclerosis Patients with Walking Impairment

Description
The MS Center at EvergreenHealth is conducting a research study of an investigational medication for walking impairment in multiple sclerosis (MS).

Currently enrolling

Who may be eligible to participate?
Patients with impaired walking, but able to complete a 25-foot timed walk (walking aids acceptable if used consistently). Other inclusion and exclusion criteria may apply.

Investigator: Theodore Brown, MD, MPH

For more information: contact EvergreenHealth Research Services at 425.899.5385 or email EvergreenResearch@evergreenhealth.com


DREAM

A Double-blind, CrossoveR, placebo-controlled Study to compare the Effects of Nighttime Administration of suvorexant in Patients with Multiple Sclerosis fatigue and insomnia

Description
The EvergreenHealth Multiple Sclerosis Center is conducting a randomized, double-blind, placebo-controlled, cross-over trial to assess the safety, tolerability, and efficacy of suvorexant (Belsomra®) in treating insomnia in adults with multiple sclerosis (MS) and fatigue.

Currently enrolling

Who may be eligible to participate?
Patients 18-75 years of age with a confirmed diagnosis of Multiple Sclerosis and Insomnia Disorder. Patients must be on a stable regimen of disease modifying therapy with no MS exacerbations for 60 days prior to screening.

What does participation involve?
This study will assess whether suvorexant (Belsomra®) is more effective than placebo in treating insomnia and fatigue in people with MS. Enrolled patients will come to the study site for 4 visits (45-90 minutes each) during the study. Patients will also have 3 or more phone conversations with a study coordinator.

Investigator: Theodore Brown, MD, MPH

For more information: contact EvergreenHealth Research Services at 425.899.5385 or email EvergreenResearch@evergreenhealth.com